NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction

Summary

NP202 is an experimental drug being developed by Armaron Bio Pty Ltd for potential use as a treatment for people after they have had a heart attack (MI).

Timeline

Start

2015-10

Primary completion

2017-12

Completion

2018-02

Outcome

Missed primary endpoint

paper For the primary end point of change in LVESVi from baseline to 3 months, there was no significant difference PMID 33851966 ↗

paper (-3.53 [-9.24 to 4.81] mL/m2) (P = .78). PMID 33851966 ↗

Publications

• Boyle AJ, Schultz C, Selvanayagam JB, Moir S, Kovacs R, Dib N, Zlotnick D, Al-Omary M, Sugito S, Selvarajah A, Collins N, McLachlan G. Calcium/Calmodulin-Dependent Protein Kinase II Delta Inhibition and Ventricular Remodeling After Myocardial Infarction: A Randomized Clinical Trial. JAMA Cardiol. 2021 Jul 1;6(7):762-768. doi: 10.1001/jamacardio.2021.0676.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NP202	Unknown	1000 mg	Oral

Indications